RxDoctor Payments Data

Michel Darazi

Neurology · Santa Fe Springs, CANPI 1003286550

Payments from drug & device makers

$9,545in general payments, 2019–2025

Across 143 payments — averaging $66.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Grifols USA, LLC$2K
  • UCB, Inc.$539
  • Novartis$473
  • Vanda Pharmaceuticals Inc.$287
  • TG Therapeutics, Inc.$284
  • plus $2K from 17 others

What the payments were for

  • Speaking & faculty fees$3,80640%
  • Travel & lodging$1,42815%
  • Food & beverage$4,31045%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,545 in reported general payments places this provider in the 70th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$42,677
Medicare patients
157
Services billed
305

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate11$103,839
Aimovig AutoinjectorErenumab-Aooe13$9,354
Memantine Hcl283$5,114
Lacosamide15$3,584
Levetiracetam38$1,867
Donepezil Hcl182$1,646
Gabapentin149$1,112
Carbamazepine ErCarbamazepine14$1,083
Atorvastatin Calcium114$1,079
Mirtazapine55$987
Carbidopa-LevodopaCarbidopa/Levodopa35$661
Duloxetine Hcl13$604
Amitriptyline Hcl79$592
Escitalopram Oxalate106$583
Olanzapine39$579

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$82$103,83911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,996 neurology providers in California.

Other neurology in Santa Fe Springs

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →